Agios

AGIO NASDAQ
42.40
-0.10
-0.24%
After Hours: 42.40 0 0.00% 17:58 08/16 EDT
Open
42.76
Prev Close
42.50
High
43.41
Low
42.13
Volume
1.01M
Avg Vol (3M)
548.20K
52 Week High
85.00
52 Week Low
38.62
% Turnover
1.72%
Market Cap
2.49B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Agios AGIO stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.
MORE >

Recently

Name
Price
%Change